Trump Announces Drug Price Cuts with Eli Lilly and Novo Nordisk

President Donald J. Trump has announced new drug pricing agreements with Eli Lilly and Novo Nordisk to significantly lower the cost of several widely used medications. The reductions, introduced through the TrumpRx initiative, target GLP-1 receptor agonists and insulin—two of the highest-cost therapeutic categories in the U.S. healthcare system.

Under the program, the monthly price of Ozempic and Wegovy will fall from $1,000 and $1,350 to $350 when purchased through TrumpRx. Eli Lilly’s Zepbound and investigational drug Orforglipron will also be available for an average of $346 per month. Novo Nordisk’s insulin products, including NovoLog and Tresiba, will be priced at $35 per monthly supply. Additionally, Eli Lilly will offer Emgality for $299 per pen and Trulicity at $389 per month.

The Administration has indicated that these changes will deliver savings to both patients and government programs. Medicare prices for Ozempic, Wegovy, Mounjaro, and Zepbound will be set at $245—less than half the cost under prior federal pricing benchmarks. State Medicaid programs will gain access to the same reduced rates. For the first time, Medicare will cover obesity drugs Wegovy and Zepbound for patients with qualifying conditions, with beneficiaries paying a copay of $50 per month.

President Trump characterized the announcement as an opportunity to reverse national trends in obesity and chronic disease. According to the Centers for Disease Control and Prevention, 40% of American adults are affected by obesity. The Administration also framed the move as part of a broader effort to rebalance the global pharmaceutical market, noting that the United States—home to less than five percent of the world’s population—accounts for roughly 75% of global pharmaceutical profits.

The agreement requires Eli Lilly and Novo Nordisk to provide “Most-Favored-Nation” pricing for new medicines and guarantee similar access for all State Medicaid programs. Concurrently, both manufacturers have committed to strengthening domestic supply chains. Novo Nordisk will invest an additional $10 billion to expand its U.S. production capacity, while Eli Lilly has announced $27 billion in new U.S. manufacturing investments.

Click here for the original news story.